Table of Contents
In a small open-label pilot of five adults with fibromyalgia, psilocybin-assisted therapy was reported to be safe and well tolerated, with no serious adverse events. Several participants showed clinically meaningful reductions in pain severity and related symptoms at one month. These are very early findings from a single small trial.
- No serious adverse events occurred. Temporary rises in blood pressure and heart rate during dosing stayed within predefined limits and resolved by the end of each session.
- Multiple symptom domains improved. Several participants reported reductions in pain severity, pain interference, anxiety, and sleep disturbance, along with modest gains in chronic pain acceptance at one-month follow-up.
- The therapy combined psilocybin with structured psychotherapy. The protocol included preparatory sessions, two psilocybin dosing visits spaced two weeks apart, and four integration sessions after each dose.
- Larger controlled trials are needed. The authors explicitly stated that the study’s limitations mean results cannot establish whether psilocybin-assisted therapy is safe and effective for fibromyalgia more broadly.
- Model
- human
- Sample
- 5 adult women with fibromyalgia
- Dose
- Two psilocybin dosing sessions, spaced 2 weeks apart (exact mg dose not reported in source)
- Design
- Open-label pilot clinical trial with preparatory, dosing, and integration sessions
- Key outcome
- No serious adverse events; several participants reported clinically meaningful symptom improvements at one-month follow-up
- Main limitation
- Extremely small sample of five participants, no control group, no blinding, single-center
What the Research Examined
This was an open-label pilot clinical trial, the first of its kind to examine psilocybin-assisted therapy (PAT) specifically for fibromyalgia. It was conducted by Jacob S. Aday, PhD, and colleagues at the University of Michigan and published in Frontiers in Pain Research in 2025. The study enrolled five adult women with fibromyalgia, a condition the authors describe as a prototypical nociplastic pain disorder rooted in altered centralized pain processing, one for which existing pharmacotherapy and physical interventions tend to offer only minimal relief.
The treatment protocol was structured in three phases. Two preparatory therapy sessions came first, establishing therapeutic rapport and providing education about psilocybin, the session structure, and safety protocols. Two psilocybin dosing sessions followed, separated by two weeks, with therapists maintaining a supportive and non-directive presence throughout. Near the close of each dosing session, participants were invited to describe their experience without therapist interpretation. Four integration sessions then followed each dosing visit, focused on processing insights and translating them into cognitive and behavioral change. This layered structure is consistent with approaches described in the broader body of psilocybin-assisted therapy research, where set, setting, and post-session integration are considered central to outcomes.
Safety monitoring included tracking blood pressure and heart rate during dosing sessions. The primary outcomes covered overall fibromyalgia symptom burden and specific domains including pain severity, pain interference, anxiety, sleep disturbance, and chronic pain acceptance, assessed at a one-month follow-up. The authors were candid that the small sample size and absence of a control group mean these findings are preliminary and hypothesis-generating rather than conclusive.
What the Findings Show
- Serious adverse events.None were reported across all five participants during the trial.
- Cardiovascular monitoring.Transient increases in blood pressure and heart rate occurred during dosing sessions but remained within predefined safety ranges and resolved by the end of treatment.
- Mild side effects.Four of the five participants reported mild, short-lived headaches following dosing sessions.
- Symptom outcomes at one month.Several participants experienced clinically meaningful reductions in pain severity, pain interference, anxiety, and sleep disturbance, along with modest gains in chronic pain acceptance. Participants generally reported improvements across overall fibromyalgia symptom domains.
It is worth holding these numbers carefully. With five participants, no placebo arm, and no blinding, the improvements observed cannot be separated from expectation effects, the therapeutic relationship, or natural fluctuation in fibromyalgia symptoms over time. The authors themselves underscored this, calling for larger, controlled trials with more clinically translational designs before any conclusions about safety or efficacy can be drawn.
Can psilocybin-assisted therapy help with fibromyalgia pain?
Research is at a very early stage. A 2025 pilot study of five adults found psilocybin-assisted therapy was well tolerated and that several participants reported reduced pain severity and related symptoms at one month. Without a control group or larger sample, no conclusions about effectiveness can be drawn yet.
What This Is, and What It Is Not
This is This is an open-label pilot clinical trial involving five adult women with fibromyalgia, designed primarily to assess safety and generate preliminary data on symptom outcomes.
This is not This is not a randomized controlled trial and cannot establish that psilocybin-assisted therapy is safe or effective for fibromyalgia. It is not medical advice, and psilocybin remains a controlled substance in most jurisdictions. Anyone living with chronic pain should consult a qualified healthcare provider about their options.
Our Take
Fibromyalgia sits in a difficult place in modern medicine: a condition that is real, disabling, and poorly served by available treatments. The fact that a small group of researchers thought to ask whether a sacrament with deep roots in human healing traditions might reach a kind of suffering that conventional pharmacology largely fails to address feels significant, even before the data matures. Five participants cannot tell us much about efficacy. They can tell us that people with fibromyalgia were willing to engage with this work, that the experience was tolerable, and that something shifted for several of them. That is worth following with care and rigor.
If you are living with chronic pain, or you hold space for someone who is, we recognize how exhausting the search for relief can be. The science here is new and limited, and we would never ask you to replace medical care with hope alone. What we do invite is curiosity: to follow this research as it develops, to learn about the broader landscape of psilocybin science, and to bring your questions and your experience into community. The Church of Psychedelics holds space for all of it, the uncertainty, the longing, and the slow, careful work of discovering what healing might look like.
Frequently Asked Questions
What is psilocybin-assisted therapy for fibromyalgia?
It is an experimental protocol that pairs psilocybin sessions with structured psychotherapy, including preparatory sessions before dosing and integration sessions afterward. A 2025 pilot study was the first to test this approach specifically in adults with fibromyalgia, enrolling five participants.
Was psilocybin safe for fibromyalgia patients in this study?
In this very small pilot of five adults, no serious adverse events were reported. Temporary increases in blood pressure and heart rate during dosing resolved by session end. Four participants had mild, brief headaches after dosing. Larger trials are needed to fully characterize safety.
How many people were in the fibromyalgia psilocybin study?
Five adult women with fibromyalgia participated in the open-label pilot trial conducted at the University of Michigan and published in Frontiers in Pain Research in 2025. The authors acknowledged this sample is too small to draw firm conclusions.
Did psilocybin reduce pain in fibromyalgia patients?
Several of the five participants reported clinically meaningful reductions in pain severity and pain interference at one-month follow-up. Because there was no control group, it is not possible to separate the effect of psilocybin from placebo effects or the therapeutic relationship.
When will there be larger psilocybin trials for fibromyalgia?
The study authors called for larger, controlled trials with more clinically translational designs. No specific follow-up trials were announced in the published findings. This 2025 pilot is intended to provide the safety and feasibility data needed to justify and design such future studies.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
